Company intelligence / Profile preview

Xellia Pharmaceuticals

Ownership: Private
Employees: ~1600
Development stage: Commercial

Overview

Xellia Pharmaceuticals supplies both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), with a focus on injectable anti-infective drugs. The company’s products are widely used in hospitals globally to treat severe bacterial infections. It has recently expanded its US manufacturing capabilities to include aseptically filled premix bags for critical care therapies.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (notably antibiotics/anti-infectives)
Industry: Biotech

Drug pipeline

2 assets

vancomycin

Commercial

Indications: Bacterial infections

1 more asset in the full pipeline.

Request access →

Partnerships

Hikma Pharmaceuticals plc – Acquired part of the US product portfolio in June 2024

Beyond the preview

Go deeper on Xellia Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xellia Pharmaceuticals.

Explore the full profile